COPD Exacerbation Acute Clinical Trial
Official title:
Manual Hyperinflation Versus Diaphragmatic Proprioceptive Neuromuscular Facilitation on Pulmonary Functions in Mechanically Ventilated Patients
the goal of this clinical trial is to compare between to important physiotherapy modalities applied on mechanically ventilated COPD patients the the main question the study aim to answer is which one of the two modalities has the better effect on mechanically ventilated patients with COPD patients will get manual hyperinflation technique and PNF technique \ researchers will compare MHI with PNF and will take a control group also
Status | Recruiting |
Enrollment | 60 |
Est. completion date | April 1, 2024 |
Est. primary completion date | March 1, 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 50 Years to 60 Years |
Eligibility | Inclusion Criteria: - Patients will be included in the study if they have the following criteria: 1. Sixty male mechanically ventilated patients. They will be ventilated on pressure support (PS) mode of MV with this setting (Positive end-expiratory pressure [PEEP]) less than 8 cm H2O, FiO2 0.4 or less, SpO2 higher than 90) due to AECOPD. 2. Their Glasgow Coma Scale score will be ranged from 13 to 15. 3. Their age between 50 and 60 years old. 4. Their BMI will be ranged from 25 to 34.9 kg/m2. 5. Moderate (GOLD 2) and severe (GOLD 3) stages of COPD according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) grading system for the severity of COPD. Exclusion Criteria: - The patients will be excluded from this study if they have one of the following criteria: Fever above 38.3 °C. Unstable hemodynamics. Thoracic or abdominal surgery that preclude the use of PNF exercises. Chest trauma such as rib fracture, flail chest and thoracic vertebra fracture or chest burns. Peripheral and central nervous system diseases. Active lung infection like tuberculosis. Active bleeding as alveolar hemorrhage, hemoptysis. Spinal cord injuries involved the phrenic nerve. Severe cardiac complications due to COPD. |
Country | Name | City | State |
---|---|---|---|
Egypt | Gamal Abdelnasser Hospital | Alexandria | Aleksandria |
Lead Sponsor | Collaborator |
---|---|
omar hasham mohamed |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Blood gases analysis | Each patient will be informed about the purpose of the test and how it will be done with keeping the explanation brief and in simple terms.
Each patient will be informed to assume a relaxed comfortable position with loose clothes. Arterial blood samples will be taken via arterial line which is accessible and less painful. The collected arterial blood sample will be sent for laboratory investigation according to ICU department laboratory communication protocol of Gamal Abdel Nasser Hospital. The test will be conducted for all patients pre and post the treatment program duration. |
immediately after the intervention | |
Primary | C- reactive protein analysis | Each patient will be informed about the purpose of the test and how it will be done with keeping the explanation brief and in simple terms.
Each patient will be instructed to assume a relaxed comfortable position with loose clothes. Initial step, phlebotomist will secure a snug rubber band around patient's upper arm, and the patient will be asked to pump his fist several times. Then phlebotomist will palpate the vein, and will cleanse with an alcohol prep pad. Then practitioner will introduce a needle into the vein, and will draw a vial of blood. After that the practitioner will remove the band, then remove the needle and apply pressure to venipuncture site up to one minute. A bandage will be applied over the site. The test will be conducted for all patients pre and post the treatment program duration. Normal finding for C-reactive protein (CRP) is < 1.0 mg/dL or <10.0 mg/L (SI units) (< 3 mg/L for high-sensitivity CRP [hs-CRP]), |
immediately after the intervention | |
Primary | Assessment of weaning parameters | The weaning process will be indicated according to the following criteria; Adequate oxygenation" PaO2/FIO2 ratio = 200, FIO2= 0.40, PaO2 = 60, PaCO2 and PEEP = 5 cmH2O", PH = 7.30, Respiratory rate = 45 bpm, Heart rate = 140 bpm, RSBI = 8 breaths/min/ml/kg body weight, Hemodynamic stability" no or minimal vasopressors or inotropes", Appropriate level of conscious, No continuous sedation infusion nor neuromuscular blocking agents, Afebrile, Adequate hemoglobin =8 g/dl and/or no evidence of hemorrhage | during the assessment time | |
Primary | Oxygenation Index | Oxygenation index is the better indicator for defining of lung injury compared to the PaO2/FiO2 ratio as it includes mean airway pressure (MAP), also it is an important determinant of oxygenation of acute respiratory failure, which evaluated according the following equation (PaO2/ FiO2) <300 mmHg with or without elevated arterial carbon dioxide tension (PaCO2) (Liu et al., 2015). OI is a commonly used to assess the severity of hypoxic respiratory failure (HRF) and persistent pulmonary hypertension OI = mean airway pressure MAP (in cmH2O) × FiO2 × 100 ÷ PaO2 . Where FiO2: Fraction of inspired oxygen in percent. MAP: Mean airway pressure in mmHg. FiO2: Fraction of inspired oxygen. PaO2: Partial pressure of oxygen in arterial blood in mmHg. The oxygenation index will be recorded for all patients pre and post the treatment program duration. | immediately after the intervention | |
Primary | Assessment of chest expansion | Each patient will be informed about the purpose of the test and how it will be done with keeping the explanation brief and in simple terms.
Each patient will assume a comfortable half lying suping position. Marking will be done at 3 levels; axillary, nipple and xiphisterna. Patient will be asked to first take some normal breaths as a breath control technique for relaxation. Then will be asked to exhale completely and then inhale maximally as much as he can and hold breath for a second. The difference between maximum exhalation and inhalation will be recorded during holding breath using a measuring tape at all three-level mentioned above. This procedure will be repeated three times and then the best value will be recorded The chest expansion will be measured for all patients pre and post the treatment program duration |
immediately after the intervention | |
Secondary | Weaning success rate: | Weaning success defined as spontaneous breathing without mechanical support for at least 48 hours. Weaning success rate, a proportion of successfully weaned patients to total number of patients receiving a treatment program, was recorded for three study groups post the treatment program duration | immediately after the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05418777 -
Treatment of Pneumocystis in COPD (the TOPIC Study)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Completed |
NCT03286855 -
Effectiveness of Vibrating Mesh Versus Small Volume Nebuliser in Chronic Obstructive Pulmonary Disease (COPD)
|
N/A | |
Recruiting |
NCT06021990 -
Clopidogrel for the Prevention of Exacerbations in Severe COPD
|
Phase 3 | |
Completed |
NCT05218525 -
Testing a Prediction Algorithm Into a Running Telehealth System for Patients With COPD
|
N/A | |
Recruiting |
NCT06149494 -
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
|
Phase 2 | |
Recruiting |
NCT05734365 -
COPD-ICU Multicentre Prospective Observational Register
|
||
Completed |
NCT03464695 -
Automated Oxygen Delivery by O2matic to Patients Admitted With an Exacerbation in COPD
|
N/A | |
Recruiting |
NCT04881409 -
Nasal High-flow Compared to Non-invasive Ventilation in Treatment of Acute Acidotic Hypercapnic Exacerbation of Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT05182294 -
Tolerance and Acute Effects of a New HFNT Nasal Cannula
|
N/A | |
Completed |
NCT04821869 -
ProAir Digihaler in COPD Disease Management: A Real World Study
|
||
Recruiting |
NCT06274957 -
The Effect of Airway and Chest Wall Oscillation on Respiratory Functions in COPD Patients in Acute Exacerbation
|
N/A | |
Recruiting |
NCT05783544 -
Impact of A. Lumbricoides on Pulmonary Aspergillosis Development
|
N/A | |
Recruiting |
NCT06331416 -
Multiparametric Home Telemonitoring of Patients With Chronic Obstructive Pulmonary Disease Exacerbation
|
N/A | |
Not yet recruiting |
NCT05703919 -
Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease
|
Phase 4 | |
Not yet recruiting |
NCT06419062 -
The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 2
|
||
Not yet recruiting |
NCT06419036 -
The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 1
|
||
Recruiting |
NCT05764993 -
Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention
|
Phase 2 | |
Completed |
NCT06040931 -
Airway Inflammation, Small Airways Dysfunction, and Frequency of Exacerbations in COPD
|
N/A | |
Active, not recruiting |
NCT04192175 -
Identification of Patients Admitted With COPD Exacerbations and Predicting Readmission Risk Using Machine Learning
|